

# **Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with autoimmune rheumatic diseases: A systematic review and meta-analysis**

**Qinyi Su<sup>1,2,3#</sup>, Xinmiao Wang<sup>2,3</sup>, Yongzhi Li<sup>2,3</sup>, Jiexiang Zhang<sup>2,3</sup>, Cairui Bai<sup>2,3</sup>, Xuechun Wang<sup>2,3</sup>, Liu Yang<sup>2,3</sup>, Jingting Zhang<sup>2,3</sup>, Sheng-Xiao Zhang<sup>1,2,3\*</sup>**

1 Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.


2 Shanxi Provincial Key Laboratory of Rheumatism Immune Microecology, The Shanxi Medical University, Taiyuan, Shanxi, China.

3 Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, China.


\*Sheng-Xiao Zhang is corresponding author.

Sheng-XiaoZhang: Phone number:+8618734823329; E-mail address:zhangshengxiaol@sxmu.edu.cn;

Present address: 382. Wuyi Road. Taiyuan. Shanxi.



**Figure S1:** Funnel plot. (A)CD4<sup>+</sup>. (B)CD8<sup>+</sup>. (C)NK. (D)Th1. (E)Th2. (F)Th17. (G)Treg. (H)Th1/Th2. (I)Th17/Treg.



**Figure S2:** Funnel plot. (A)DAS-28 scores. (B)SELENA-SLEDAI scores. (C)CDASI scores.

